Title: Associations of C-reactive protein to lymphocyte ratio and  metabolic-dysfunction-
associated steatotic liver disease: evidence from NHANES 2017-2018
Version: 6 Date: 16 Sep 2024
Reviewer:  Maged Tharwat Elghannam
Reviewer's report:
The authors discuss the relation between MASLD and CLR and the possibility of its use as a
potential biomarker for identifying MASLD. MAFLD has a high prevalence all over the world
thanks to the increased prevalence of obesity and DM. It ranges from MAFLD to NASH to
liver cirrhosis up to HCC. Not all cases of NAFLD develop NASH or liver cirrhosis and its
complications.
Comments:
What are the reasons you chose the covariates?
What is the relation between CLR in a normal population? This represents a control for your
cases.
How can you use this CLR to differentiate between MAFLD and MASH?
I think it is mandatory to test this relationship before and after medications and compare this
with cap values before and after therapy.
Title: Associations of C-reactive protein to lymphocyte ratio and  metabolic-dysfunction-
associated steatotic liver disease: evidence from NHANES 2017-2018
Version: 6 Date: 16 Sep 2024
Reviewer:  Maged Tharwat Elghannam
Reviewer's report:
The authors discuss the relation between MASLD and CLR and the possibility of its use as a
potential biomarker for identifying MASLD. MAFLD has a high prevalence all over the world
thanks to the increased prevalence of obesity and DM. It ranges from MAFLD to NASH to
liver cirrhosis up to HCC. Not all cases of NAFLD develop NASH or liver cirrhosis and its
complications.
Comments:
What are the reasons you chose the covariates?
What is the relation between CLR in a normal population? This represents a control for your
cases.
How can you use this CLR to differentiate between MAFLD and MASH?
I think it is mandatory to test this relationship before and after medications and compare this
with cap values before and after therapy.
Please review this paper.
user
Title: Associations of C-reactive protein to lymphocyte ratio and  metabolic-dysfunction-
associated steatotic liver disease: evidence from NHANES 2017-2018
Version: 6 Date: 16 Sep 2024
Reviewer:  Maged Tharwat Elghannam
Reviewer's report:
The authors discuss the relation between MASLD and CLR and the possibility of its use as a
potential biomarker for identifying MASLD. MAFLD has a high prevalence all over the world
thanks to the increased prevalence of obesity and DM. It ranges from MAFLD to NASH to
liver cirrhosis up to HCC. Not all cases of NAFLD develop NASH or liver cirrhosis and its
complications.
Comments:
What are the reasons you chose the covariates?
What is the relation between CLR in a normal population? This represents a control for your
cases.
How can you use this CLR to differentiate between MAFLD and MASH?
I think it is mandatory to test this relationship before and after medications and compare this
with cap values before and after therapy.
assistant